Globus Medical completes acquisition of Nevro Corp.
Globus Medical (NYSE: GMED) has completed its acquisition of Nevro Corp., a medical device company specializing in chronic pain treatment solutions. The strategic acquisition expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity in the neuromodulation space.
The deal aims to accelerate market penetration of Nevro's high-frequency technology for chronic pain treatment. Nevro's common stock has ceased trading on the NYSE as of April 3, 2025. Globus Medical plans to discuss the acquisition's benefits during its first quarter earnings conference in May.
Morgan Stanley & Co. and BofA Securities, Inc. served as financial advisors to Globus Medical and Nevro Corp., respectively.
Globus Medical (NYSE: GMED) ha completato l'acquisizione di Nevro Corp., un'azienda di dispositivi medici specializzata in soluzioni per il trattamento del dolore cronico. Questa acquisizione strategica amplia la presenza di Globus Medical nel mercato muscoloscheletrico, sbloccando un opportunità di mercato da 2,5 miliardi di dollari nel settore della neuromodulazione.
L'accordo mira ad accelerare la penetrazione di mercato della tecnologia ad alta frequenza di Nevro per il trattamento del dolore cronico. Le azioni ordinarie di Nevro hanno smesso di essere scambiate sulla NYSE a partire dal 3 aprile 2025. Globus Medical prevede di discutere i benefici dell'acquisizione durante la sua conferenza sugli utili del primo trimestre a maggio.
Morgan Stanley & Co. e BofA Securities, Inc. hanno svolto il ruolo di consulenti finanziari per Globus Medical e Nevro Corp., rispettivamente.
Globus Medical (NYSE: GMED) ha completado su adquisición de Nevro Corp., una empresa de dispositivos médicos especializada en soluciones para el tratamiento del dolor crónico. Esta adquisición estratégica amplía la presencia de Globus Medical en el mercado musculoesquelético, desbloqueando una oportunidad de mercado de 2.5 mil millones de dólares en el espacio de la neuromodulación.
El acuerdo tiene como objetivo acelerar la penetración en el mercado de la tecnología de alta frecuencia de Nevro para el tratamiento del dolor crónico. Las acciones comunes de Nevro han dejado de cotizar en la NYSE a partir del 3 de abril de 2025. Globus Medical planea discutir los beneficios de la adquisición durante su conferencia de ganancias del primer trimestre en mayo.
Morgan Stanley & Co. y BofA Securities, Inc. actuaron como asesores financieros de Globus Medical y Nevro Corp., respectivamente.
글로부스 메디컬 (NYSE: GMED)은 만성 통증 치료 솔루션을 전문으로 하는 의료 기기 회사인 네브로 코퍼레이션을 인수 완료했습니다. 이 전략적 인수는 글로부스 메디컬의 근골격계 시장 내 존재감을 확대하고, 신경 조절 분야에서 25억 달러의 시장 기회를 열어줍니다.
이번 거래는 네브로의 고주파 기술의 시장 침투를 가속화하는 것을 목표로 합니다. 네브로의 보통주는 2025년 4월 3일부로 NYSE에서 거래가 중단되었습니다. 글로부스 메디컬은 5월에 열리는 1분기 실적 발표 회의에서 인수의 이점을 논의할 계획입니다.
모건 스탠리 & 코와 BofA 증권, Inc.는 각각 글로부스 메디컬과 네브로 코퍼레이션의 재무 자문 역할을 수행했습니다.
Globus Medical (NYSE: GMED) a finalisé son acquisition de Nevro Corp., une entreprise de dispositifs médicaux spécialisée dans les solutions de traitement de la douleur chronique. Cette acquisition stratégique élargit la présence de Globus Medical sur le marché musculosquelettique, débloquant une opportunité de marché de 2,5 milliards de dollars dans le domaine de la neuromodulation.
L'accord vise à accélérer la pénétration du marché de la technologie haute fréquence de Nevro pour le traitement de la douleur chronique. Les actions ordinaires de Nevro ont cessé d'être négociées à la NYSE à partir du 3 avril 2025. Globus Medical prévoit de discuter des avantages de l'acquisition lors de sa conférence sur les résultats du premier trimestre en mai.
Morgan Stanley & Co. et BofA Securities, Inc. ont agi en tant que conseillers financiers pour Globus Medical et Nevro Corp., respectivement.
Globus Medical (NYSE: GMED) hat die Übernahme von Nevro Corp., einem Medizintechnikunternehmen, das auf Lösungen zur Behandlung von chronischen Schmerzen spezialisiert ist, abgeschlossen. Diese strategische Übernahme erweitert die Präsenz von Globus Medical im muskuloskelettalen Markt und eröffnet eine Marktchance von 2,5 Milliarden Dollar im Bereich der Neuromodulation.
Das Geschäft zielt darauf ab, die Marktdurchdringung der Hochfrequenztechnologie von Nevro zur Behandlung von chronischen Schmerzen zu beschleunigen. Die Stammaktien von Nevro haben am 3. April 2025 den Handel an der NYSE eingestellt. Globus Medical plant, die Vorteile der Übernahme während seiner Ergebnispräsentation im ersten Quartal im Mai zu erörtern.
Morgan Stanley & Co. und BofA Securities, Inc. fungierten jeweils als Finanzberater für Globus Medical und Nevro Corp.
- Unlocks $2.5 billion market opportunity in neuromodulation
- Expands product portfolio in chronic pain treatment solutions
- Gains access to Nevro's differentiated high-frequency technology
- Strengthens presence in musculoskeletal market
- None.
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain.
“We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain,” said Dan Scavilla, president and CEO of Globus Medical.
The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a
Globus Medical plans to discuss the closing of the acquisition and the anticipated benefits of the expanded product offering during its first quarter earnings conference in May.
Nevro Corp. common stock ceased trading on the New York Stock Exchange prior to the open of the market on April 3, 2025. Further information about the transaction can be found in the Form 8-Ks filed with the SEC today by Nevro Corp. and Globus Medical, respectively.
Financial and Legal Advisors
Morgan Stanley & Co. LLC served as financial advisor to Globus Medical, and Wyrick Robbins Yates & Ponton LLP served as legal advisor. BofA Securities, Inc. served as financial advisor to Nevro Corp. and Latham & Watkins LLP served as legal advisor.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at https://www.globusmedical.com/.
About Nevro Corp.
Headquartered in Redwood City, California, Nevro Corp. is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in the treatment of chronic pain. Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. Nevro also provides minimally invasive treatment options for patients suffering from chronic sacroiliac joint pain.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the Nevro business, trends in the medical industry and the ability of Globus Medical and Nevro to: (i) successfully integrate and achieve anticipated synergies, (ii) manage our growth, (iii) sustain profitability, (iv) sustain demand for products, (v) compete successfully (including without limitation success in convincing surgeons to use Globus Medical or Nevro products and the ability to attract and retain sales and other personnel), (vi) rapidly develop and introduce new products, (vii) develop and execute successful business strategies, (viii) comply with changes and applicable laws and regulations that are or may become applicable to Globus Medical and/or Nevro, (ix) safeguard our intellectual property, and (x) succeed in defending against legal proceedings in addition to general economic conditions and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of each of Globus Medical and Nevro contained in each company’s most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in each company’s Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, each of Globus Medical and Nevro operates in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for Globus Medical and Nevro to predict all risk factors and uncertainties, nor can we assess the impact of all factors on the Globus Medical business and Nevro business, respectively, or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Globus Medical and Nevro undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Investor contact:
Brian Kearns
610-930-1800
investors@globusmedical.com
Media contact:
Moran Chavez
media@globusmedical.com
FAQ
What is the market opportunity size for GMED following the Nevro acquisition?
When will GMED discuss the benefits of the Nevro acquisition?
What technology does GMED gain from the Nevro acquisition?
When did Nevro Corp. stock cease trading on the NYSE?
